No abstract

The objective of the study was to develop and validate simple, authentic and stability indicating high performance thin-layer chromatographic method for determination of Canagliflozin in bulk and pharmaceutical formulations as per ICHQ2 R1 Guidelines. HPTLC aluminium plates Precoated with Silica Gel 60F254 using Toluene: Ethyl acetate: Methanol (2:2:1, v/v/v) as mobile phase were used for the chromatographic separation and it was validated with different parameters such as Linearity, Precision, Accuracy, Robustness, Ruggedness, Limit of Detection (LOD) and Limit of Quantification (LOQ). Also, Forced degradation study was carried out in different mediums. The densitometric analysis of the spots was performed at 290 nm. A Linear data over the range of 10-500ng/spot with a good correlation coefficient of 0.9988 unfolds linear relationship between area and concentration in calibration curve. The LOD and LOQ were found to be 0.39 and 1.19 respectively. A recovery of Canagliflozin in tablet formulation was observed in the range of 99.04-99.82%. Percentage assay of Canagliflozin tablets (INVOKANA ® ) was found to be 99.8%. Forced degradation studies of canagliflozin showed the degradation in acidic, alkaline, photolytic and oxidation but were most stable in thermal degradation. The proposed method is definite, meticulous and reproducible and can be used for routine analysis of Canagliflozin in bulk and pharmaceutical dosage form.

Objective: To develop and validate simple, sensitive, precise, rapid and cost effective method for determination of Canagliflozin in bulk and pharmaceutical formulations as per ICH Guidelines. Methods: A simple double beam UV Spectrophotometric method has been developed and validated with different parameters such as Linearity, Precision, Repeatability, Limit of Detection (LOD), Limit of Quantification (LOQ), Accuracy, Robustness and Ruggedness. Results: Canagliflozin in methanol shows maximum absorbance at 290 nm. Beer's law was obeyed in the concentration range of 5-10 mcg mL-1, The LOD and LOQ were found to be 0.084 mcg/ml and 0.255 mcg/ml respectively. A recovery of Canagliflozin in tablet formulation was observed in the range of 80.00-120.00%. Percentage assay of Canagliflozin tablets (INVOKANA ®) was found to be more than 99%. Conclusion: The proposed method is precise, accurate and reproducible and can be used for routine analysis of Canagliflozin in bulk and pharmaceutical dosage form.

Objective: To develop and validate simple, authentic and stability indicating high performance liquid chromatographic method for determination of Canagliflozin in bulk and pharmaceutical formulations as per ICH Q2 R1 Guidelines. Methods: A C 18 Column (250×4.6 mm, 5 μm particle size) with a mobile phase consisting of Acetonitrile: orthophosphoric acid in a ratio of 55:45 v/v was employed for the chromatographic study. A flow rate of 1 ml/min with an injection volume of 20 μL was selected for this study and the proposed method was validated with different parameters such as Linearity, Precision, Accuracy, Robustness, Ruggedness, Limit of Detection (LOD) and Limit of Quantification (LOQ). Results: The separation was achieved at a temperature of 30ºC and the eluents were observed by photo diode array detector set at 290 nm. A linear range of 1-6 μg/ ml with a correlation coefficient of 0.998 unfolds good linear relationship between area and concentration in calibration curve. The retention time obtained was at 6.29 min. The LOD and LOQ were found to be 0.41 μg/ml and 1.24 μg/ml respectively. A recovery of Canagliflozin in tablet formulation was observed in the range of 99.6-99.8%. Percentage assay of Canagliflozin tablets (INVOKANA ®) was found to be 99.92%. The stability of the method was demonstrated by forced degradation studies of drug in which it was degraded under conditions of hydrolysis (acidic and alkaline), oxidation, photolytic and thermal stress as per ICH guideline Q1A (R2). Conclusion: The proposed method is definite, meticulous and reproducible and can be used for routine analysis of Canagliflozin in bulk and pharmaceutical dosage form.

No abstract